Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings

Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chi ...